PD-1

RMP1-14 is an IgG-like immunoglobulin antibody against mouse PD-1 that can block PD-1 PD-L1 signaling; its isotype control antibody is Mouse IgG2a kappa, Isotype Control.

Atezolizumab is an antibody inhibitor, a humanized monoclonal antibody, IgG1, which targets PD-L1 and blocks the interaction of PD-L1 with PD-1. Atezolizumab has antitumor activity and promotes T-cells to attack tumor cells.

Avelumab, a fully human IgG1 anti-PD-L1 monoclonal antibody, exhibits potential antibody-dependent cell-mediated cytotoxicity.

Nivolumab is a monoclonal antibody, a humanized IgG4 antibody to PD-1. Nivolumab has antitumor activity and is used in the treatment of melanoma, non-small cell lung cancer, renal cell carcinoma and others.

Pembrolizumab (MK-3475) is a humanized monoclonal antibody inhibiting the PD-1 receptor and the first in the class of agents called the HER2 dimerization inhibitors that impairs the ability of HER2 to bind to other members of the HER family.

Durvalumab (MEDI 4736) is a humanized monoclonal antibody targeting PD-L1. It can block the interaction of PD-L1 with PD-1 and CD80, with IC50 values of 0.1 and 0.04 nM, respectively. Durvalumab is often used in combination with platinum-based compounds for the treatment of non-small cell lung cancer and advanced hepatocellular carcinoma cells.

Sintilimab (IBI308) is a humanized IgG4 monoclonal antibody with significant anti-tumor activity that restores endogenous anti-tumor T-cell responses by binding to PD-1 and thereby blocking the interaction of PD-1 with its ligands (PD-L1 and PL-L2).Sintilimab is used in combination with other compounds for the treatment of classical Hodgkin's lymphoma, non-cellular lung cancer and esophageal cancer. Sintilimab is used in combination with other compounds to treat classical Hodgkin's lymphoma, non-small cell lung cancer and esophageal cancer.

Camrelizumab (SHR-1210) is a human IgG4-κ monoclonal antibody with high affinity directed against PD-1, binding PD-1 with an affinity of up to 3 nM and inhibiting PD-1 PD-L1 with an IC50 of 0.70 nM. Camrelizumab exhibits anti-tumor activity and is well tolerated in cancers, including NSC-LC, ESCC, Hodgkin's lymphoma, and advanced HCC.

Tislelizumab (BGB-A317) is an IgG4 class monoclonal antibody targeting human programmed death receptor-1 (PD-1) with antitumor activity that inhibits the binding of Fcγ receptor to macrophages and can be used to study advanced squamous non-small cell lung cancer.

Ezabenlimab (BI-754091) is a humanized monoclonal antibody targeting programmed cell death protein-1 with antitumor activity that blocks the interaction of PD-1 with PD-L1 and PD-L2, inhibits tumor growth in vivo, and can be used to study advanced solid tumors.

Latikafusp (AMG 256) is a fusion protein that is a PD-1 blocker and IL-21R agonist with antitumor activity.Latikafusp initiates and prolongs cytotoxicity and memory T-cell activity and induces the generation of immunogenicity-mediated responses.

Spartalizumab (PDR001) is a humanized immunoglobulin G4 monoclonal antibody that selectively binds to PD-1 at low concentrations, exhibiting high activity. It blocks the interaction with PD-L1 and PD-L2, making it suitable for studying undifferentiated thyroid cancer (ATC).

Nofazinlimab (CS1003) is a human anti-PD-1 IgG4 monoclonal antibody used to study unresectable hepatocellular carcinoma (uHCC) and metastatic colorectal cancer.

Feladilimab (GSK3359609) is an IgG4 monoclonal antibody that is an ICOS agonist. Feladilimab binds to ICOS-expressing T cells, induces IFNγ, and increases PD-1 L1 expression. Feladilimab has anti-tumor activity and can be used to study cancer.

Anti-Mouse PD-L1 Antibody (10F.9G2) is an IgG-class antibody against mouse PD-L1.

Peresolimab, a humanized IgG1-κ antibody, targets PD-1 and may activate physiological immune inhibitory pathways, thereby restoring immune homeostasis [1] [2].

Acrixolimab is a humanized IgG4-κ monoclonal antibody that selectively targets PD-1 [1] [2].

Sasanlimab (PF-06801591), a humanized IgG4-κ antibody, selectively targets PD-1 and is primarily produced in Chinese Hamster Ovary (CHO) cells [1].

Rezilimab is a bispecific antibody that targets PD-1 PD-L1 and mediates antibody-dependent cell cytotoxicity (ADCC) in cancer research [1] [2].

Rosnilimab, a humanized IgG1-κ antibody, specifically targets PD-1 [1] [2].

Visugromab, a GDF-15 neutralizing IgG4 monoclonal antibody (mAb), demonstrates potent efficacy in treating PD-1 PD-L1 relapsed refractory metastatic solid tumors [1].

Pidilizumab (CT-011), a humanized IgG1κ anti-PD-1 monoclonal antibody, serves as a DLL1 antagonist with potential applications in researching hematologic malignancies [1].

Lipustobart is an IgG4-kappa humanized monoclonal antibody targeting PDCD1 (programmed cell death 1, PD1, PD-1, CD279), with immunostimulant and antineoplastic activity [1].

Danburstotug (IMC-001), an immunostimulant and antineoplastic [1], is a humanized IgG1-lambda monoclonal antibody targeting CD274 (PDL1, B7 homologue 1, B7H1).